Astellas Pharma to Transfer Manufacturing Plant, Business to Delpharm

Novartis will invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities and a new research hub.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

Rising demand for peptide-based therapeutics prompts the launch of this new peptide research center, which will offer services across peptide synthesis, discovery, and advanced modalities.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Wider adoption of single-use technologies and systems is aligning with sustainability goals for the industry.

Process consistency and robustness, analytical excellence, and regulatory compliance are essential in the scale-up of biosimilars.